Pages that link to "Q42936448"

The following pages link to Metformin and energy metabolism in breast cancer: from insulin physiology to tumour-initiating stem cells. (Q42936448):

Displaying 32 items.

• Adenosine monophosphate-activated protein kinase in diabetic nephropathy (Q26745623) (← links)
• Interactions between tumor cells and microenvironment in breast cancer: a new opportunity for targeted therapy (Q27012888) (← links)
• Do metformin a real anticarcinogen? A critical reappraisal of experimental data (Q30863461) (← links)
• The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer (Q33893799) (← links)
• Metformin for aging and cancer prevention (Q34424886) (← links)
• Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics (Q35051171) (← links)
• Gerosuppressant Metformin: less is more (Q35052060) (← links)
• Getting to the source: selective drug targeting of cancer stem cells (Q35156404) (← links)
• Metformin and the ATM DNA damage response (DDR): Accelerating the onset of stress-induced senescence to boost protection against cancer (Q35645149) (← links)
• Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue (Q35737581) (← links)
• Recent progress in targeting cancer (Q35740782) (← links)
• Metformin: Multi-faceted protection against cancer (Q35764409) (← links)
• Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals. (Q35770306) (← links)
• Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs (Q36209145) (← links)
• Metformin: Midlife maturity, maiden charm (Q36436404) (← links)
• Metformin limits the tumourigenicity of iPS cells without affecting their pluripotency (Q36460656) (← links)
• Risk assessment, disease prevention and personalised treatments in breast cancer: is clinically qualified integrative approach in the horizon? (Q36738790) (← links)
• Accelerated geroncogenesis in hereditary breast-ovarian cancer syndrome (Q37022075) (← links)
• Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions (Q37091483) (← links)
• AMPK Activators as a Drug for Diabetes, Cancer and Cardiovascular Disease (Q37138635) (← links)
• Association between metformin therapy and mortality after breast cancer: a population-based study (Q37193432) (← links)
• Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin (Q37299288) (← links)
• Metformin: do we finally have an anti-aging drug? (Q37530252) (← links)
• Targeting metabolism for cancer treatment and prevention: metformin, an old drug with multi-faceted effects (Q38016107) (← links)
• Postmenopausal breast cancer, androgens, and aromatase inhibitors. (Q38097730) (← links)
• Metabostemness: a new cancer hallmark. (Q38261030) (← links)
• Activation of AMP-activated protein kinase (AMPK) provides a metabolic barrier to reprogramming somatic cells into stem cells (Q38418048) (← links)
• Acquired resistance to metformin in breast cancer cells triggers transcriptome reprogramming toward a degradome-related metastatic stem-like profile (Q39247899) (← links)
• Metformin is synthetically lethal with glucose withdrawal in cancer cells. (Q39312255) (← links)
• The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells (Q41831013) (← links)
• Fatty acid synthase (FASN) as a therapeutic target in breast cancer. (Q50044384) (← links)
• Metformin lowers the threshold for stress-induced senescence: a role for the microRNA-200 family and miR-205. (Q53184000) (← links)